England's National Health Service will soon offer nivolumab as a quick injection for cancer patients. This new method cuts ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

The complete remission of a testicular cancer patient receiving Mink Therapeutics Inc.’s allogeneic, off-the-shelf invariant natural killer T-cell therapy Agent-797 with nivolumab drove the company’s ...

Most patients with advanced melanoma treated with pre-surgical immunotherapy remained alive and free of disease four years post-treatment.

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...

Modified Herpes Virus as a Weapon Against Skin Cancer? A new study suggests it might work—even for metastases deep within the body that have been difficult to target. This combination therapy could ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

Scientists found that a genetically engineered herpes simplex virus, when combined with immunotherapy, reduced or eliminated tumors.

University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically ...

Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.